FDA Inspection 1271320 — Cipla Ltd.

Cipla Ltd. — FEI 3005857289

The FDA completed an inspection of Cipla Ltd. on May 30, 2025 in Bangalore. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
May 30, 2025
Fiscal Year
2025
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Bangalore (India)